GlaxoSmithKine and Merck Serono, both existing investors of Auxogyn, have participated in a funding round for the newly merged company, dubbed Progyny.
US-based women’s reproductive health company Auxogyn has merged with US-based fertility technology provider Fertility Authority to form Progyny, raising funding from pharmaceutical companies GlaxoSmithKline and Merck Serono in the process.
The respective corporate venturing units of GlaxoSmithKline and Merck Serono, SR One and Merck Serono Ventures, were joined by other existing Auxogyn backers including Kleiner Perkins Caufield & Byers (KPCB) and TPG Biotech.
The size of the funding round has not been disclosed, but a regulatory filing for Auxogyn dated…
